Why Celldex Therapeutics Stock Is Back on Investors’ Radar

Celldex Therapeutics (CLDX) has been added to several Russell growth indices and filed a US$115.9 million shelf registration for common stock, a combination that can reshape how different investors view the company.

At a share price of US$38.96, Celldex Therapeutics has shown strong momentum recently, with a 30 day share price return of 36.41% and a year to date share price return of 44.24%. The 1 year total shareholder return of 73.46% contrasts with a modest 3 year total shareholder return of 7.12% and a negative 5 year total shareholder return, suggesting enthusiasm has picked up more recently, likely helped by the Russell index additions and the fresh shelf registration plan.

If Celldex Therapeutics has caught your attention, it can be useful to see what else is moving in healthcare related AI and data driven therapies, including 40 healthcare AI stocks

After a sharp move higher and fresh index attention, the question for Celldex Therapeutics is simple: lean in at today’s price or wait and hope for a better entry as the valuation picture comes into focus next.

Preferred Price-to-Book Multiple of 6.7x for Celldex Therapeutics: Is It Justified?

Celldex Therapeutics is currently trading at a P/B of 6.7x, which sits well above both the US Biotechs industry average of 2.8x and the peer average of 3.7x, so the market is clearly paying a premium for this stock relative to its balance sheet value.

The P/B ratio compares the company’s market value to its net assets. This can be a useful gauge for early stage or unprofitable biopharma companies where earnings are not yet a reliable anchor. At 6.7x book value, investors are effectively assigning substantial value to Celldex Therapeutics’ pipeline and future potential rather than its current $865K in revenue and reported loss of $283.646m.

When measured against peers, Celldex Therapeutics does not just sit slightly above the pack. It trades at more than double the US Biotechs industry average P/B and meaningfully higher than the 3.7x peer average. That level of premium indicates that the market is already pricing in strong future execution and growth, which is a high bar for any unprofitable company to meet based purely on expectations.

Result: Price-to-book of 6.7x (OVERVALUED)

However, Celldex Therapeutics still faces clear risks, including its US$283.646m loss and its dependence on early stage antibody programs that may not progress as expected.

Another View on Celldex Therapeutics: DCF Versus Book Value

The earlier P/B snapshot painted Celldex Therapeutics as expensive relative to its assets, but our DCF model points in the opposite direction. At a share price of $38.96, Celldex Therapeutics is trading about 61.3% below an estimated future cash flow value of $100.70, which frames the stock as undervalued under that method. For investors, the real tension is which story to trust more: a rich balance sheet multiple or a generous cash flow outlook.

Before leaning too heavily on either view, it is worth understanding how sensitive long term cash flow models can be to assumptions, especially for a company that is currently unprofitable and forecast to remain so over the next three years, Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Celldex Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With Celldex Therapeutics pulling in both optimism and concern, now is a good time to review the numbers yourself and decide where you stand on the risk reward balance. To see how the positives stack up against the potential downsides in one place, take a closer look at the 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond Celldex Therapeutics?

If Celldex Therapeutics has sharpened your appetite for opportunities, do not stop here. Widen your search with focused tools that surface stocks matching very different goals.

• Target potential mispricing in quality companies by reviewing the 44 high quality undervalued stocks that combine solid fundamentals with appealing value signals.
• Strengthen your income sleeve by scanning the 9 dividend fortresses built around higher yield stocks that also emphasize resilience.
• Prioritize resilience and capital preservation by checking the 72 resilient stocks with low risk scores that highlights companies with lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.